Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Human-Centered Design of a Low Molecular Weight Heparin Order Set to Reduce Medication Errors.

DʼSouza A, Wu P, Jung L, Nungaray K, Richman M.

J Healthc Qual. 2019 Jan/Feb;41(1):e7-e12. doi: 10.1097/JHQ.0000000000000171.

PMID:
30614929
2.

Comparative Analysis of Dry and Wet Porometry Methods for Characterization of Regular and Cross-Linked Virus Removal Filter Papers.

Gustafsson S, Westermann F, Hanrieder T, Jung L, Ruppach H, Mihranyan A.

Membranes (Basel). 2018 Dec 20;9(1). pii: E1. doi: 10.3390/membranes9010001.

3.

Random Mutagenesis, Clonal Events, and Embryonic or Somatic Origin Determine the mtDNA Variant Type and Load in Human Pluripotent Stem Cells.

Zambelli F, Mertens J, Dziedzicka D, Sterckx J, Markouli C, Keller A, Tropel P, Jung L, Viville S, Van de Velde H, Geens M, Seneca S, Sermon K, Spits C.

Stem Cell Reports. 2018 Jul 10;11(1):102-114. doi: 10.1016/j.stemcr.2018.05.007. Epub 2018 Jun 14.

4.

CpG Island Methylation Correlates with the Use of Alternative Promoters for USP44 Gene Expression in Human Pluripotent Stem Cells and Testes.

Tropel P, Jung L, André C, Ndandougou A, Viville S.

Stem Cells Dev. 2017 Aug 1;26(15):1100-1110. doi: 10.1089/scd.2017.0057. Epub 2017 Jul 10.

PMID:
28520534
5.

Translation of Expanded CGG Repeats into FMRpolyG Is Pathogenic and May Contribute to Fragile X Tremor Ataxia Syndrome.

Sellier C, Buijsen RAM, He F, Natla S, Jung L, Tropel P, Gaucherot A, Jacobs H, Meziane H, Vincent A, Champy MF, Sorg T, Pavlovic G, Wattenhofer-Donze M, Birling MC, Oulad-Abdelghani M, Eberling P, Ruffenach F, Joint M, Anheim M, Martinez-Cerdeno V, Tassone F, Willemsen R, Hukema RK, Viville S, Martinat C, Todd PK, Charlet-Berguerand N.

Neuron. 2017 Jan 18;93(2):331-347. doi: 10.1016/j.neuron.2016.12.016. Epub 2017 Jan 5.

6.

What is really driving cell-surface interactions? Layer-by-layer assembled films may help to answer questions concerning cell attachment and response to biomaterials.

Sergeeva YN, Huang T, Felix O, Jung L, Tropel P, Viville S, Decher G.

Biointerphases. 2016 Mar 10;11(2):019009. doi: 10.1116/1.4943046.

PMID:
26964531
7.

ONSL and OSKM cocktails act synergistically in reprogramming human somatic cells into induced pluripotent stem cells.

Jung L, Tropel P, Moal Y, Teletin M, Jeandidier E, Gayon R, Himmelspach C, Bello F, André C, Tosch A, Mansouri A, Bruant-Rodier C, Bouillé P, Viville S.

Mol Hum Reprod. 2014 Jun;20(6):538-49. doi: 10.1093/molehr/gau012. Epub 2014 Feb 5.

PMID:
24501429
8.

Peri-prosthetic femoral fractures treated with the uncemented Wagner revision stem.

Marx A, Beier A, Jung L, Lohmann CH, Halder AM.

Hip Int. 2012 May-Jun;22(3):286-91. doi: 10.5301/HIP.2012.9246.

PMID:
22740275
9.

Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID mice.

Zamboni WC, Jung LL, Strychor S, Joseph E, Zamboni BA, Fetterman SA, Sidone BJ, Burke TG, Curran DP, Eiseman JL.

Invest New Drugs. 2008 Oct;26(5):399-406. doi: 10.1007/s10637-007-9109-9. Epub 2008 Feb 2.

PMID:
18246299
10.

Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy.

Israeli RS, Ryan CW, Jung LL.

J Urol. 2008 Feb;179(2):414-23. Review.

PMID:
18076933
11.

Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.

Zamboni WC, Ramanathan RK, McLeod HL, Mani S, Potter DM, Strychor S, Maruca LJ, King CR, Jung LL, Parise RA, Egorin MJ, Davis TA, Marsh S.

Invest New Drugs. 2006 Sep;24(5):393-401.

PMID:
16505951
12.

Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts.

Zamboni WC, Jung LL, Egorin MJ, Hamburger DR, Joseph E, Jin R, Strychor S, Ramanathan RK, Eiseman JL.

Clin Cancer Res. 2005 Jul 1;11(13):4867-74.

13.

Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies.

Ramanathan RK, Ramalingam S, Egorin MJ, Belani CP, Potter DM, Fakih M, Jung LL, Strychor S, Jacobs SA, Friedland DM, Shin DM, Chatta GS, Tutchko S, Zamboni WC.

Cancer Chemother Pharmacol. 2005 Apr;55(4):354-360. doi: 10.1007/s00280-004-0909-8. Epub 2004 Oct 27.

PMID:
15723261
14.

Discovery, Development, and clinical applications of bortezomib.

Jung L, Holle L, Dalton WS.

Oncology (Williston Park). 2004 Dec;18(14 Suppl 11):4-13. Review.

15.

Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors.

Jung LL, Ramanathan RK, Egorin MJ, Jin R, Belani CP, Potter DM, Strychor S, Trump DL, Walko C, Fakih M, Zamboni WC.

Cancer Chemother Pharmacol. 2004 Dec;54(6):487-96. Epub 2004 Aug 18.

PMID:
15322760
16.

Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors.

Zamboni WC, Jung LL, Egorin MJ, Potter DM, Friedland DM, Belani CP, Agarwala SS, Wong MM, Fakih M, Trump DL, Jin R, Strychor S, Vozniak M, Troetschel M, Ramanathan RK.

Clin Cancer Res. 2004 Aug 1;10(15):5058-64.

17.

Clinical use of the respiratory quotient obtained from indirect calorimetry.

McClave SA, Lowen CC, Kleber MJ, McConnell JW, Jung LY, Goldsmith LJ.

JPEN J Parenter Enteral Nutr. 2003 Jan-Feb;27(1):21-6.

PMID:
12549594
18.

Darbepoetin alfa: a review of its use in patients with cancer.

Jung LL, Schwartz RN.

Cancer Pract. 2002 Nov-Dec;10(6):327-30. Review. No abstract available.

PMID:
12406056

Supplemental Content

Loading ...
Support Center